Over the course of thirty years, Mr. Rein has handled litigations relating to a wide variety of fields ranging from HIV diagnostic kits to vaccines, from coffee decaffeination to numerous pharmaceuticals such as generic versions of Claritin, Lipitor, Nasonex and Zantac. See, e.g., Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc., 217 F.Supp.3d 782 (D. Del. 2016) (Trial victory relating to a generic version of Nasonex based on Mr. Rein’s examination of the parties’ expert witnesses including Merck’s expert who used one of the world’s most powerful X-ray diffraction facilities, the synchrotron at Argonne National Laboratory, in an unsuccessful attempt to prove infringement).onal Laboratory, in an unsuccessful attempt to prove infringement).
Frederick H. Rein
Fred Rein is a U.S. Registered Patent Attorney and currently of counsel at Goodwin where he was a partner for many years and helped co-found the firm’s IP litigation group in New York. He is the incoming Chair of the Israel Practice committee of the American Intellectual Property Law Association, and also serves on the Patents Committee of the New York City Bar Association and the Tech Division committee of UJA.
In 2017, Mr. Rein was honored as a recipient of The Legal Aid Society’s Pro Bono Publico Award. He also mentored the winners of the Anti-Defamation League’s 2017 Summer Associate Research Program competition in New York.
Boston College Law School
New York University
Rensselaer Polytechnic Institute